Market revenue in 2023 | USD 505.4 million |
Market revenue in 2030 | USD 919.9 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Immunohistochemistry |
Fastest growing segment | Digital Pathology and Workflow |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunohistochemistry, In situ Hybridization, Primary & Special Staining, Digital Pathology and Workflow, Anatomic Pathology, Molecular Pathology |
Key market players worldwide | Roche Holding AG ADR, Abbott Laboratories, Thermo Fisher Scientific Inc, Siemens AG, Danaher Corp, BioMerieux SA, Qiagen NV, BD, Merck KGaA, GE Aerospace, Agilent Technologies Inc, Biogenex, Cell Signaling Technology, Bio SB, DiaGenic |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to tissue diagnostics market will help companies and investors design strategic landscapes.
Immunohistochemistry was the largest segment with a revenue share of 25.7% in 2023. Horizon Databook has segmented the China tissue diagnostics market based on immunohistochemistry, in situ hybridization, primary & special staining, digital pathology and workflow, anatomic pathology, molecular pathology covering the revenue growth of each sub-segment from 2018 to 2030.
Supportive government regulations and investments by private organizations have led to rapid increase in cancer research in this country. Rapid increase in nanoscience R&D in China has attracted worldwide attention, thereby boosting revenue generation.
High incidence of cervical cancer remains a major problem in China, which provides lucrative growth opportunities for diagnostics devices, such as tissue diagnostics. In 2014, cell staining techniques was developed to detect cervical cancer, which helped distinguish between neoplastic and normal cells, based on morphology & color retained.
In 2015, IHC assay was performed on BARF using V600E (VE1) mouse monoclonal primary antibody on a Ventana slide strainer to detect BARF mutation in tumor patients in China. BARF is considered as a potential diagnostic and prognostic marker for cancer detection in clinical diagnostics.
Horizon Databook provides a detailed overview of country-level data and insights on the China tissue diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into China tissue diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account